Two clinical stage biotech companies with drug discovery platforms based on artificial intelligence are to merge, creating a company with a portfolio of wholly-owned assets as well as collaborations with five big pharma companies. Recursion Pharmaceuticals Inc of Salt Lake City, US, is to have a 74% stake in the new company, which will take the Recursion name and be led by Chris Gibson, the current Recursion chief executive. The partner is Exscientia Plc of Oxford, UK, a smaller AI company founded in 2017 to focus on small molecule drug design.
